IDEXX Laboratories Elects Sophie Vandebroek to Board of Directors

      IDEXX Laboratories Elects Sophie Vandebroek to Board of Directors

PR Newswire

WESTBROOK, Maine, July 15, 2013

WESTBROOK, Maine, July 15, 2013 /PRNewswire/ --IDEXX Laboratories, Inc.
(NASDAQ: IDXX) today announced the unanimous election of Sophie V. Vandebroek,
PhD as a member of the Company's Board of Directors effective July 15, 2013.
Dr. Vandebroek fills a vacancy on the Board for a Class II director, the term
for which ends at the Company's 2014 annual meeting of stockholders. At that
meeting, Dr. Vandebroek is expected to stand for re-election by stockholders
as a Class II director with a three-year term expiring in 2017.


"I am very pleased to welcome Sophie to our Board of Directors," commented
Jonathan Ayers, Chairman of the Board and Chief Executive Officer of the
Company. "IDEXX is entering a critical new phase in its evolution as a leading
pet healthcare innovation company. IDEXX is unique in its ability to serve
practicing veterinarians around the world with a broad range of integrated
diagnostic and information technology-based products and services. To further
build upon this opportunity, the Company will need to expand its skills and
aptitudes. With Sophie's outstanding depth of knowledge and experience in
technology and business processes as well as track record of innovation and
managing balanced R&D portfolios for large global enterprises, she is ideally
suited to help guide and advise the Board and the Company's management team."

Dr. Vandebroek, 51, has been an executive with Xerox Corporation (NYSE: XRX),
the world's leading enterprise for business process and document management,
since 2002. Most recently, Dr. Vandebroek has been serving as Xerox's Chief
Technology Officer and Corporate Vice President, as well as President of the
Xerox Innovation Group since 2006. She is responsible for overseeing Xerox's
research centers in Europe, Asia, Canada and the United States as well as the
Palo Alto Research Center. Prior to her current positions, from 2002 to 2005,
Dr. Vandebroek was Chief Engineer of Xerox and Vice President of the Xerox
Engineering Center.

Dr. Vandebroek earned an undergraduate degree in engineering and a master's
degree in electro-mechanical engineering from Katholieke Universiteit Leuven,
Leuven, Belgium, and she holds a PhD in electrical engineering from Cornell
University in Ithaca, New York. Dr. Vandebroek is a Fellow of the Institute of
Electrical & Electronics Engineers, a Fulbright Fellow, and a Fellow of the
Belgian-American Educational Foundation. Dr. Vandebroek was inducted into the
Women in Technology International Hall of Fame and elected into the Royal
Flemish Academy for Arts & Sciences. Dr. Vandebroek holds more than a dozen
U.S. patents and serves on the advisory council of the Dean of Engineering at
MIT. Dr. Vandebroek has also served as a member of the Board of Directors of
Analogic Corporation, a designer and manufacturer of advanced medical imaging
and airport security systems, since 2008.

"IDEXX has a tremendous track record for global innovation in the pet
healthcare industry as well as in its other lines of business," commented Dr.
Vandebroek. "The Company has a unique opportunity, by leveraging its diverse
range of diagnostic modalities and expanding its information technology
platforms and capabilities, to truly advance veterinary medical care. It's an
honor to help guide IDEXX into this exciting next phase of growth and

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving
practicing veterinarians around the world with a broad range of diagnostic and
information technology-based products and services. IDEXX products enhance the
ability of veterinarians to provide advanced medical care, improve staff
efficiency and build more economically successful practices. IDEXX is also a
worldwide leader in providing diagnostic tests and information for livestock
and poultry and tests for the quality and safety of water and milk.
Headquartered in Maine, IDEXX Laboratories employs more than 5,400 people and
offers products to customers in over 175 countries.

Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management's current expectations and beliefs, as well
as a number of assumptions concerning future events. These statements are
subject to risks, uncertainties, assumptions and other important factors.
Readers are cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those expressed or
implied. The reports filed by the Company pursuant to United States securities
laws contain discussions of these risks and uncertainties. The Company assumes
no obligation to, and expressly disclaims any obligation to, update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise. Readers are advised to review the Company's filings with
the United States Securities and Exchange Commission (which are available from
the SEC's EDGAR database at, at various SEC reference facilities
in the United States and via the Company's website at

Contact: Ed Garber, Director, Investor Relations, (207) 556-8155

SOURCE IDEXX Laboratories, Inc.

Press spacebar to pause and continue. Press esc to stop.